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Nesiritide as an adjunctive therapy in adult patients with heart failure
undergoing high-risk cardiac surgery
Louis E. Samuels, MD,a Elena C. Holmes, CRNP,a and Lee Letwin, MD,b Wynnewood, Pa
The use of nesiritide has been shown to be efficacious inpatients with decompensated heart failure.1 The role ofnesiritide in cardiac surgery, however, remains undeter-mined. The purpose of this report is to document our
initial experience with nesiritide as an adjunctive therapy in
adult patients with heart failure undergoing high-risk cardiac
surgery.
Patients and Methods
Between October 2003 and January 2004, a total of 12 patients
with advanced heart failure underwent cardiac surgery by a single
surgeon (L.E.S.) at a single center. The use of nesiritide was
determined by 4 intraoperative criteria: (1) congestive heart failure
(New York Heart Association functional class III-IV), (2) pulmo-
nary hypertension (systolic pulmonary arterial pressure [PAP]
40 mm Hg), (3) low cardiac index (CI. 2.0 L/[min · m2]), and
(4) elevated central venous pressure (CVP, 15 mm Hg). Patients
with and without renal insufficiency were included. Nesiritide was
instituted as an infusion (0.01 g/[kg · min]) after placement of a
Swan-Ganz catheter (Edwards Lifesciences, Irvine, Calif). The
infusion was continued after the operation until the desired hemo-
dynamic state was established. Other cardiac medications were
administered as needed to augment cardiac output (eg, milrinone),
systemic blood pressure (eg, norepinephrine), and arrhythmia con-
trol (eg, amiodarone). Hemodynamic parameters (systemic blood
pressure, PAP, CVP, and CI) were measured immediately before,
during, and 24 hours after surgery. In addition, the serum creati-
nine level was measured before surgery and on the first postoper-
ative day. The urinary output was measured continuously and
recorded 24 hours after admission to the intensive care unit.
Results
There were 8 women and 4 men with a mean age of 67.1 years
(range 45-83 years). There were 4 coronary artery bypass grafting
operations, 4 valvular operations, 3 combined coronary and val-
vular operations, and 1 ventricular assist device procedure (Table
1). Before nesiritide infusion, the mean systolic blood pressure was
115 mm Hg, the mean systolic PAP was 63.5 mm Hg, the mean
CVP was 22.5 mm Hg, and the mean CI was 1.7 L/(min · m2). The
mean baseline serum creatinine level was 1.3 g/dL. After the
operation, the mean systolic blood pressure was 114 mm Hg, the
mean systolic PAP was 40.1 mm Hg, the mean CVP was 14 mm
Hg, and the mean CI was 2.5 L/(min · m2) (Table 2). The mean
urinary output for the first 24 postoperative hours was 2290 mL.
The mean postoperative serum creatinine level was 1.4 g/dL. The
mean ventilator time, intensive care unit stay, and postoperative
length of stay were 9.5 hours, 2.3 days, and 8 days, respectively.
There were no deaths and 6 morbidities: 1 surgical hemorrhage
requiring re-exploration, 2 cases of prolonged mechanical ventila-
tion (24 hours), and 3 new-onset atrial fibrillations. No patient
required discontinuation of nesiritide before the establishment
of an optimal hemodynamic state. Nesiritide infusion remained
at 0.01 g/(kg · min) during the entire infusion period. The
mean duration of nesiritide therapy was 35 hours (range 24-48
hours).
Discussion
Nesiritide, human recombinant B-type natriuretic peptide, is
among a family of natriuretic peptides with vasodilatory effects. Its
role in the treatment of decompensated congestive heart failure is
well established. Hemodynamic efficacy with direct and indirect
cardiovascular and renal responses has been demonstrated.1 Ne-
siritide has been shown to directly augment coronary artery per-
fusion,2 reduce pulmonary capillary wedge pressure, PAP, and
CVP, and indirectly improve cardiac output with no effect on heart
rate.3 Nesiritide has also been shown to increase urinary sodium
excretion (natriuresis) and urinary volume while preserving creat-
inine clearance.4 Finally, nesiritide suppresses the release of nor-
epinephrine, the release of endothelin 1, and the renin-angiotensin-
aldosterone axis.5
The role of nesiritide in adult cardiac surgery is undefined. A
limited number of studies have examined the use of nesiritide in
various settings.6-8 Truong and associates,6 for example, described
24 patients requiring inotropic support (milrinone) who were eval-
uated for transplantation after a 24- to 48-hour nesiritide infusion.
As a result of the improved hemodynamics, 14 patients were
directly listed and 7 additional patients received elective—as op-
posed to emergency—left ventricular assist devices. Similarly,
nesiritide therapy has been found to act favorably as an adjunct
to the treatment of decompensated heart failure immediately
after cardiac transplantation.7 Finally , Moazami and col-
leagues8 have described positive cardiovascular and renal ef-
fects in 2 patients given nesiritide after coronary artery bypass
grafting.8
Our study adds to the experience of others in helping to define
the role of nesiritide in cardiac surgery. As the complexity of
cardiac surgery becomes more apparent, with sicker patients and
weaker hearts, advanced pharmacologic therapies become neces-
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sary for management. The properties of nesiritide lend themselves
to the heart failure population, whether medical or surgical. In an
effort to define nesiritide’s role and application, we sought to
establish a protocol in which a nesiritide infusion was instituted in
patients with heart failure undergoing cardiac surgery. Specific
parameters were defined in the operating room, and a simple
infusion scheme was established. The infusion was kept constant
until the desired hemodynamic status was achieved, often in com-
bination with other cardiac medications (eg, milrinone). We found
little role for loop diuretic and low-dose (“renal dose”) dopamine.
The use of norepinephrine was not uncommon, a consequence of
the combined vasodilatory characteristics of milrinone and nesirit-
ide. The duration of norepinephrine use was less than 48 hours and
the dosage range was low. We did not observe any ventricular
arrhythmias.
Conclusions
In our opinion, nesiritide therapy serves as an important adjunct in
the management of patients with heart failure undergoing cardiac
surgery. When combined with other cardiac medications, such as
milrinone, a therapeutic balance of cardiovascular and renal effects
is safe and practical.
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Case Procedure Age (y) Sex Presentation EF (%) NYHA class
1 OPCAB 72 F Pulmonary edema 20 III
2 AVR and CABG 75 F Pulmonary edema 30 III
3 OPCAB 83 F Pulmonary edema 25 III
4 AVR 74 M Pulmonary edema 20 III
5 OPCAB 63 F Acute MI 30 III
6 AVR and CABG 58 F Pulmonary edema 10 III
7 MVR 53 M Pulmonary edema 25 IV
8 OPCAB 68 F Acute myocardial infarction 20 III
9 LVAD 45 M Ischemic cardiomyopathy 10 IV
10 OPCAB 77 M Pulmonary edema 25 III
11 AVR and CABG 76 F Pulmonary edema 30 III
12 AVR and MVR 61 F Pulmonary edema 35 IV
EF, Ejection fraction; NYHA, New York Heart Association; OPCAB, off-pump coronary artery bypass grafting; AVR, aortic valve replacement; CABG, coronary
artery bypass grafting; MI, myocardial infarction; MVR, mitral valve replacement; LVAD, left ventricular assist device.
TABLE 2. Hemodynamics
Case Procedure
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Preop Postop Preop Postop Preop Postop Preop Postop
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12 AVR and MVR 112 105 45 37 18 12 1.9 2.5
Average 116 114 64 40 23 14 1.7 2.5
SBP, Systemic blood pressure; sPAP, systolic PAP; Preop, preoperative; Postop, postoperative; OPCAB, off-pump coronary artery bypass grafting; AVR,
aortic valve replacement; CABG, coronary artery bypass grafting; MVR, mitral valve replacement; LVAD, left ventricular assist device.
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Transit-time flow measurement cannot detect wrong anastomosis of an
internal thoracic artery with the cardiac vein in coronary artery surgery
Yoshiyuki Takami, MD, and Hiroshi Masumoto, MD, Kasugai, Japan
In coronary artery surgery transit-time flow measurement isuseful to determine graft patency and to detect graft failureintraoperatively. Previous reports have demonstrated the ac-curacy and reproducibility of this noninvasive and simple
procedure.1-5 In this report, however, we describe a case of wrong
anastomosis of the left internal thoracic artery (LITA) with the
cardiac vein, which could not be detected with transit flow mea-
surement.
Clinical Summary
A 72-year-old man with effort angina was referred for coronary
artery surgery. His coronary angiograms revealed occlusion of the
distal right coronary artery and significant stenosis of the left main
stem, the proximal left anterior descending artery, and the proxi-
mal left circumflex artery. He underwent triple coronary artery
bypass grafting during cardiopulmonary bypass. The LITA was
grafted to the left anterior descending artery, the left radial artery
to the obtuse marginal branch of the left circumflex artery, and the
saphenous vein to the atrioventricular branch of the right coronary
artery. The result of transit-time flow measurement of the LITA
graft is demonstrated in Figure 1. The mean flow (Qm) was 48
mL/min, the pulsatility index ([Maximal flow  Minimal flow]/
Qm) was 1.6, and the percentage of insufficiency (Volume of
backward flow/Volume of forward flow) was 0%. The postopera-
tive angiogram revealed that the LITA had been anastomosed with
the cardiac vein (Figure 1, B), although both aorta-coronary grafts
(radial artery and saphenous vein) were patent.
Discussion
In the transit-time method it is neither necessary to know the vessel
diameter nor to perform any complex calibrating procedures.
Therefore intraoperative transit-time flow measurement has be-
come increasingly popular to check the anastomotic quality in
coronary artery bypass grafting.5 As we have already demonstrated
in the quantitative angiographic evaluation,2,3 intraoperative Qm is
closely related to the degree of the stenosis at the most stenotic
portion of the anastomosis. However, we cannot completely rely
on the Qm value to determine the anastomotic quality of the graft.
It is possible to have a patent anastomosis with a low Qm because
the optimal Qm varies with the dynamic character, including blood
pressure, heart rate, coronary resistance, and graft diameter.1,5 We
cannot necessarily judge a graft with a Qm of less than 20 mL/min
as nonpatent in the operating room. In contrast, surgeons can
consider a graft with a Qm of greater than 20 mL/min as patent.1
In addition, on the basis of the specific physiology of coronary
circulation, patent graft flow is predominantly diastolic, forming a
trapezoid-shaped waveform with a short systolic peak, as demon-
strated in Figure 2. On the contrary, there is no diastolic flow in an
occluded graft.2-4
In the patient in this report, the intraoperative Qm of the LITA
was 48 mL/min, and its flow pattern was diastolic dominant. We
considered the LITA as patent in the operating room. However, the
postoperative angiogram revealed that the LITA had been acci-
dentally anastomosed with the cardiac vein and not with the left
coronary artery that we had intended to use for anastomosis. The
arteriovenous flow pattern is similar to the arterioarterial flow
pattern in coronary circulation. Although it is uncommon to per-
form incorrect grafting of the LITA to the cardiac vein, we should
know that the transit-time flow measurement cannot differentiate
the wrong anastomosis.
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